Mediar Therapeutics and Eli Lilly Ink Deal for IPF Drug MTX-463
US-based clinical-stage biotech Mediar Therapeutics, Inc. has announced a global license agreement with Eli Lilly...
Eli Lilly
Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion
US-based Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks with compatriot firm...
Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments
UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co....
Eli Lilly China’s Neuroscience VP Jiang Yifei Departs for New Opportunities
Jiang Yifei, the current vice president of Eli Lilly (NYSE: LLY) China’s neuroscience division, has...
Eli Lilly & Co. Launches Mounjaro (Tirzepatide) in China for Diabetes and Weight Management
US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the official market launch...
Innovent Biologics Partners with Suzhou ForLong to Explore Sintilimab and FL115 Combination in Solid Tumors
China-based Innovent Biologics, Inc. (HKG: 1801) has announced a clinical study and supply agreement with...
Eli Lilly’s Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has revealed that the US Food...
Eli Lilly’s Kisunla Receives NMPA Approval for Early Alzheimer’s Disease Treatment
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced...
Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform
Shenzhen-based QuantumPharm Inc., trading as Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with...
Innovent Biologics Partners with Eli Lilly for Distribution of Jaypirca in China
China-based Innovent Biologics, Inc. (HKG: 1801) has entered into a significant distribution and promotion agreement...
EMA’s CHMP Supports Approval of Eli Lilly’s Omvoh (Mirikizumab) for Crohn’s Disease
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently...
Eli Lilly’s Imlunestrant Reduces Disease Progression in ER+/HER2- Advanced Breast Cancer: EMBER-3 Study
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has published results from the Phase...
Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL/SLL Treatment
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the...
Cambrex Partners with Eli Lilly to Enhance Clinical Development for Biotech Collaborators
US-based contract development and manufacturing organization (CDMO) Cambrex has reached an agreement with Eli Lilly...
Eli Lilly & Co. Expands Wisconsin Manufacturing Facility with $3 Billion Investment
US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the expansion of its...
Eli Lilly’s Zepbound Outperforms Wegovy in SURMOUNT-5 Weight Loss Study
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has revealed a positive readout from...
HutchMed and Innovent Biologics’ Fruzaqla-Tyvyt Combo Gets NMPA Conditional Approval for Endometrial Cancer
Chinese firms HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...
Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with...
Eli Lilly’s Tirzepatide Meets Primary Endpoints in Phase III SUMMIT Heart Failure Study
Eli Lilly and Company (NYSE: LLY), a leading US pharmaceutical corporation, has announced positive results...
Eli Lilly’s Muvalaplin Demonstrates Potent Lp(a) Reduction in Phase II Study
Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced positive results...